Advertisement

IL-6 and the acute phase response in murine atherosclerosis

  • Li Song
    Affiliations
    Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Search for articles by this author
  • Author Footnotes
    1 This work is supported by grants from the NIH (HL-56984 and AI-50514).
    Christian Schindler
    Correspondence
    Corresponding author. Fax: +1 212 543 0063.
    Footnotes
    1 This work is supported by grants from the NIH (HL-56984 and AI-50514).
    Affiliations
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 701 West, 168th Street, HHSC 1212, New York, NY 10032, USA

    Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Search for articles by this author
  • Author Footnotes
    1 This work is supported by grants from the NIH (HL-56984 and AI-50514).

      Abstract

      Numerous studies have implicated C-reactive protein (CRP) and the acute phase response (APR) in the development of atherosclerotic heart disease. Interleukin (IL)-6, which regulates both CRP expression and the APR, has also been identified as a risk factor for heart disease. To more directly evaluate the role of IL-6 in the development of atherosclerosis, IL-6 knockout mice were crossed with atherosclerosis prone LDL receptor (LDL-R) knockout mice. Lesion development was evaluated on Chow, Western type and Paigen diets. As anticipated, the Paigen diet stimulated the expression of APR genes in LDL-R[−/−] mice, but not IL-6[−/−]/LDL-R[−/−] mice. Despite this difference in acute phase response, only modest and statistically not significant differences were noted in the development of atherosclerotic lesions in LDL-R[−/−] and IL-6[−/−]/LDL-R[−/−] mice. These observations suggest that IL-6 and the acute phase response may not play as significant role in atherogenesis as other studies have indicated.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yudkin J.S.
        • Kumari M.
        • Humphries S.E.
        • Mohamed-Ali V.
        Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?.
        Atherosclerosis. 2000; 148: 209-214
        • Binder C.J.
        • Chang M.K.
        • Shaw P.X.
        • et al.
        Innate and acquired immunity in atherogenesis.
        Nat Med. 2002; 8: 1218-1226
        • Blake G.J.
        • Ridker P.M.
        Inflammatory bio-markers and cardiovascular risk prediction.
        J Intern Med. 2002; 252: 283-294
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Luc G.
        • Bard J.M.
        • Juhan-Vague I.
        • et al.
        C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1255-1261
        • Rezaie-Majd A.
        • Maca T.
        • Bucek R.A.
        • et al.
        Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1194-1199
        • Tomai F.
        • Crea F.
        • Gaspardone A.
        • et al.
        Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion.
        Circulation. 2001; 104: 1471-1476
        • Lindmark E.
        • Diderholm E.
        • Wallentin L.
        • Siegbahn A.
        Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.
        JAMA. 2001; 286: 2107-2113
        • Pradhan A.D.
        • Manson J.E.
        • Rifai N.
        • Buring J.E.
        • Ridker P.M.
        C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.
        JAMA. 2001; 286: 327-334
        • Torzewski M.
        • Rist C.
        • Mortensen R.F.
        • et al.
        C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2094-2099
        • Seino Y.
        • Ikeda U.
        • Ikeda M.
        • et al.
        Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions.
        Cytokine. 1994; 6: 87-91
        • Fattori E.
        • Cappelletti M.
        • Costa P.
        • et al.
        Defective inflammatory response in interleukin 6-deficient mice.
        J Exp Med. 1994; 180: 1243-1250
        • Alonzi T.
        • Maritano D.
        • Gorgoni B.
        • et al.
        Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver.
        Mol Cell Biol. 2001; 21: 1621-1632
        • Kopf M.
        • Baumann H.
        • Freers G.
        • et al.
        Impaired immune and acute-phase responses in interleukin-6-deficient mice.
        Nature. 1994; 368: 339-342
        • Keidar S.
        • Heinrich R.
        • Kaplan M.
        • Hayek T.
        • Aviram M.
        Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6.
        Arterioscler Thromb Vasc Biol. 2001; 21: 1464-1469
        • Huber S.A.
        • Sakkinen P.
        • Conze D.
        • Hardin N.
        • Tracy R.
        Interleukin-6 exacerbates early atherosclerosis in mice.
        Arterioscler Thromb Vasc Biol. 1999; 19: 2364-2367
        • Nakashima Y.
        • Plump A.S.
        • Raines E.W.
        • Breslow J.L.
        • Ross R.
        ApoE-deficient mice develop lesions in all phases of atherosclerosis throughout the arterial tree.
        Aterioscler Thromb. 1994; 14: 133-140
        • Elhage R.
        • Clamens S.
        • Besnard S.
        • et al.
        Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice.
        Atherosclerosis. 2001; 156: 315-320
        • Van Lenten B.J.
        • Wagner A.C.
        • Navab M.
        • Fogelman A.M.
        Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6.
        J Biol Chem. 2001; 276: 1923-1929
        • Paul A.
        • Ko K.W.
        • Li L.
        • et al.
        C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.
        Circulation. 2004; 109: 647-655
        • Roselaar S.E.
        • Daugherty A.
        Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo.
        J Lipid Res. 1998; 39: 1740-1743
        • Ishibashi S.
        • Goldstein J.L.
        • Brown M.S.
        • Herz J.
        • Burns D.K.
        Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.
        J Clin Invest. 1994; 93: 1885-1893
        • Song L.
        • Leung C.
        • Schindler C.
        Lymphocytes are important in early atherosclerosis.
        J Clin Invest. 2001; 108: 251-259
        • Lichtman A.H.
        • Clinton S.K.
        • Iiyama K.
        • et al.
        Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1938-1944
        • Vergnes L.
        • Phan J.
        • Strauss M.
        • Tafuri S.
        • Reue K.
        Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.
        J Biol Chem. 2003; 278: 42774-42784
        • Gupta S.
        • Pablo A.-M.
        • Jiang X.-C.
        • et al.
        IFN-γ potentiates atherosclerosis in apoE knock-out mice.
        J Clin Invest. 1997; 99: 2752-2761
        • Nakashima Y.
        • Raines E.W.
        • Plump A.S.
        • Breslow J.L.
        • Ross R.
        Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse.
        Arterioscler Thromb Vasc Biol. 1998; 18: 842-851
        • Jain S.K.
        • Kannan K.
        • Lim G.
        • et al.
        Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes.
        Diab Care. 2003; 26: 2139-2143
        • Merat S.
        • Casanada F.
        • Sutphin M.
        • Palinski W.
        • Reaven P.D.
        Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1223-1230
        • Tomoda H.
        • Aoki N.
        Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction.
        Am Heart J. 2000; 140: 324-328